346 related articles for article (PubMed ID: 27232854)
21. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
22. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
23. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
[TBL] [Abstract][Full Text] [Related]
24. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
25. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
26. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
28. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
29. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
30. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.
Taeb J; Asgari M; Abolhasani M; Farajollahi MM; Madjd Z
Pathol Res Pract; 2014 Jan; 210(1):18-23. PubMed ID: 24183365
[TBL] [Abstract][Full Text] [Related]
31. Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis.
Tae BS; Cho S; Kim HC; Kim CH; Kang SH; Lee JG; Kim JJ; Park HS; Cheon J; Oh MM; Kang SG
Sci Rep; 2018 Jul; 8(1):10748. PubMed ID: 30013089
[TBL] [Abstract][Full Text] [Related]
32. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy.
Desmeules P; Hovington H; Nguilé-Makao M; Léger C; Caron A; Lacombe L; Fradet Y; Têtu B; Fradet V
Diagn Pathol; 2015 Jun; 10():67. PubMed ID: 26070608
[TBL] [Abstract][Full Text] [Related]
33. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
34. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
37. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.
Mathieu R; Shariat SF; Seitz C; Karakiewicz PI; Fajkovic H; Sun M; Lotan Y; Scherr DS; Tewari A; Montorsi F; Briganti A; Rouprêt M; Lucca I; Margulis V; Rink M; Kluth LA; Rieken M; Bachman A; Xylinas E; Robinson BD; Bensalah K; Margreiter M
World J Urol; 2015 Aug; 33(8):1165-71. PubMed ID: 25344896
[TBL] [Abstract][Full Text] [Related]
38. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.
Ekici S; Cerwinka WH; Duncan R; Gomez P; Civantos F; Soloway MS; Lokeshwar VB
Int J Cancer; 2004 Oct; 112(1):121-9. PubMed ID: 15305383
[TBL] [Abstract][Full Text] [Related]
40. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]